Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain Functional Connectivity Disruption in a Large Cohort of Patients with Primary Progressive Aphasia
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (5:30 PM-6:30 PM)
10-001
To assess the functional connectivity patterns associated with each of the three variants of primary progressive aphasia (PPA) in a large cohort of patients.

Resting-state functional MRI (RS-fMRI) is promising for the investigation of specific brain functional connectivity alterations associated to PPA variants.

We enrolled 40 nonfluent (nfvPPA), 28 semantic (svPPA), and 22 logopenic (lvPPA) variants of PPA and 62 age- and sex-matched healthy controls (HC). RS-fMRI sequences were obtained from all participants, brain networks of interest were identified using an independent component analysis and were compared between groups accounting for gray matter atrophy (GIFT and BPM toolboxes, SPM12).
Compared to HC, all PPA patients showed reduced connectivity in the left posterior cingulum and inferior parietal cortex within the default mode network (DMN). Compared to HC and lvPPA, nfvPPA and svPPA patients showed: reduced connectivity in the left superior frontal and parietal gyri, and increased connectivity in the right lateral parietal cortex within the left frontoparietal network, in the bilateral insular cortices and anterior cingulum within the salience network, in the left cerebellar subregion VIII within the cerebellar network, and in the left anterior cingulate cortex within the frontostriatal network. Compared to HC, lvPPA patients showed increased connectivity in the right insula and thalamus within the salience network. 

In the three PPA variants, the DMN is affected regardless the underlying pathology. NfvPPA and svPPA cases showed common alterations within frontal networks reflecting their common frontotemporal degeneration. Compared to the other two variants, lvPPA showed increased connectivity in anterior regions of frontal networks as observed in patients with typical Alzheimer’s disease. RS-fMRI is powerful to improve the in vivo distinction between these clinical variants.
Authors/Disclosures
Federica Agosta (San Raffaele Scientific Institute)
PRESENTER 		Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Elisa Canu (Ospedale San Raffaele) The institution of Elisa Canu has received research support from Italian Ministry of Health .
Michela Leocadi, MSc (IRCCS San Raffaele Scientific Institute) Dr. Leocadi has nothing to disclose.
No disclosure on file
Giuseppe Magnani Giuseppe Magnani has nothing to disclose.
Paola Caroppo Paola Caroppo has nothing to disclose.
No disclosure on file
No disclosure on file
Ildebrando H. Appollonio, MD (Neurology Section, Dept. of Medicine and Surgery, University of Milano Bicocca) Dr. Appollonio has nothing to disclose.
Vincenzo Silani, MD, FÂ鶹´«Ã½Ó³»­ (University of Milan Medical School - IRCCS Istituto Auxologico Italiano) Dr. Silani has nothing to disclose.
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of Â鶹´«Ã½Ó³»­, Science and Technological Development of Serbia.
Paola Valsasina Paola Valsasina has nothing to disclose.
Massimo Filippi, MD, FÂ鶹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.